Literature DB >> 31469473

Chimeric G-CSF Receptor-Mediated STAT3 Activation Contributes to Efficient Induction of Cardiomyocytes from Mouse Induced Pluripotent Stem Cells.

Tasuku Tsukamoto1, Takahiro Sogo2, Tomoe Ueyama1, Shu Nakao1, Yukihiro Harada1, Dai Ihara1, Yuka Akagi1, Yasuyuki S Kida3,4, Koji Hasegawa5, Teruyuki Nagamune6, Masahiro Kawahara6, Teruhisa Kawamura1.   

Abstract

Producing a sufficient number of cardiomyocytes from pluripotent stem cells has been of great demand for cardiac regeneration therapy. However, it remains challenging to efficiently differentiate cardiomyocytes with low costs. Reportedly, granulocyte colony-stimulating factor (G-CSF) receptor (GCSFR) signaling activates signal transducers and activators of transcription (STAT) signaling and enhances cardiac differentiation from embryonic stem cells or induced pluripotent stem cells (iPSCs). To economically and efficiently produce cardiomyocytes from iPSCs through GCSFR/STAT axis activation, we constructed antibody/receptor chimeras that can respond to an inexpensive small molecule. Single-chain Fv of anti-fluorescein (FL) antibody was ligated to transmembrane/cytoplasmic domains of GCSFRs, enabling transduction of GCSFR signaling in response to FL-conjugated bovine serum albumin (BSA-FL) as an alternative ligand. Mouse iPSC lines constitutively expressing these chimeric receptors exhibited increased BSA-FL-induced STAT3 phosphorylation in a dose-dependent manner, which was abolished by an inhibitor of Janus tyrosine kinase (JAK). In addition, BSA-FL stimulation also increased the incidence of beating embryoid bodies and upregulated cardiac-specific gene expressions after differentiation in these iPSC lines. Therefore, the chimeric GCSFRs activated endogenous GCSFR signaling at least via the JAK/STAT3 pathway, thereby enhancing cardiac differentiation from iPSCs. This approach, as an economical strategy, could contribute to stem cell-based cardiac regeneration therapy.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  G-CSF; JAK/STAT pathway; cardiac differentiation; chimeric antigen receptor; pluripotent stem cell

Year:  2019        PMID: 31469473     DOI: 10.1002/biot.201900052

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  3 in total

1.  Efficacy and Safety of Granulocyte-Colony Stimulating Factor Therapy in Chagas Cardiomyopathy: A Phase II Double-Blind, Randomized, Placebo-Controlled Clinical Trial.

Authors:  Carolina T Macedo; Ticiana F Larocca; Márcia Noya-Rabelo; Roque Aras; Cristiano R B Macedo; Moisés I Moreira; Alessandra C Caldas; Jorge A Torreão; Victor M A Monsão; Clarissa L M Souza; Juliana F Vasconcelos; Milena R Bezerra; Daniela P Petri; Bruno S F Souza; Antônio G F Pacheco; André Daher; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Front Cardiovasc Med       Date:  2022-06-09

Review 2.  Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.

Authors:  Tatiana R Perry; Michelle L Roberts; Bipin Sunkara; Ragasnehith Maddula; Tyson McLeish; Jose Gomez; Julliette Lucas; David Rayan; Sahishnu Patel; Mingyu Liang; Zeljko J Bosnjak; Sherry-Ann Brown
Journal:  Curr Oncol Rep       Date:  2021-05-03       Impact factor: 5.945

Review 3.  Emerging roles of the RNA modifications N6-methyladenosine and adenosine-to-inosine in cardiovascular diseases.

Authors:  Vilbert Sikorski; Antti Vento; Esko Kankuri
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-20       Impact factor: 10.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.